zintick
CDNA CareDx+22.2%Stock moveEarnings and guidance

CareDx Stock Jumps 22% After Raising 2026 Revenue and Adjusted EBITDA Guidance

Third-quarter revenue rose 39% to $139.4 million and the company lifted its full-year outlook, while BTIG raised its price target to $92.

By Zintick Team · Editor: Kratik Mehta
Published

CDNA · Oct. 30, 2026
+22.2%
the session's move

Key points

  • Shares rose 22.2% Friday, closing at $87.41, after CareDx raised its 2026 guidance with third-quarter results.
  • Q3 revenue rose 39% to $139.4 million; GAAP net income was $19.3 million.
  • 2026 revenue guidance raised to $520 million to $530 million from $490 million to $500 million.
  • BTIG raised its price target to $92 from $81 and kept a Buy rating.

CareDx (Nasdaq: CDNA) shares rose 22.2% on Friday, Oct. 30, 2026, closing at $87.41 against a previous close of $71.52. The S&P 500 ETF (SPY) fell 1.77% over the same session. Trading volume ran at about 2.5 times its usual level.

The move followed results the company released on Oct. 29. The company filed an 8-K that day attaching its third-quarter press release. It reported revenue of $139.4 million, up 39% from a year earlier, and GAAP net income of $19.3 million, or $0.35 per diluted share, compared with $0.03 a year earlier. Adjusted EBITDA reached $30.5 million.

Guidance raised

CareDx now expects 2026 revenue of $520 million to $530 million, up from its previous range of $490 million to $500 million. Its full-year Adjusted EBITDA outlook rose to $90 million to $100 million from $66 million to $78 million.

Testing volume and Specialty Oncology

Testing Services revenue was $119.2 million, up 65% year over year, and volume reached about 75,900 tests, up 51%. The company said the results included contributions from its NavDx specialty oncology test following the Naveris acquisition closed July 1, 2026.

Analyst view

BTIG kept its Buy rating on CareDx before the open on Friday and raised its price target to $92 from $81.

The company's 10-Q filed the previous afternoon showed cash and cash equivalents of $250.5 million as of Sept. 30, 2026.

Sources

Written with AI from SEC filings and market data, and checked against those sources before publishing. Our editorial standards.

CDNA page →

Filings, figures and price history are on the CareDx page.